Practice

Disney Official, Others Talk About Switch to Biosimilars

August 13th 2020

By Tony Hagen

Article

Dismayed at the low biosimilar uptake and the lost savings, large employers are taking matters into their own hands.

At University of Missouri Health Care, Biosimilars Are Transformative but Somewhat Restricted

August 12th 2020

By Tony Hagen

Article

Pharmacy experts discuss their level of confidence with biosimilars and some of the hurdles that stand in the way of optimizing these lower-cost medicines.

Study to Evaluate Discontinuation of Biosimilar RA Treatment

August 11th 2020

By Tony Hagen

Article

Japanese investigators say more needs to be known about what happens post treatment with biosimilar infliximab in patients with rheumatoid arthritis (RA).

Sandoz Rituximab Measures Up in DLBCL

August 10th 2020

By Tony Hagen

Article

A rituximab biosimilar in diffuse large B-cell lymphoma (DLBCL) passes the real-world test with flying colors, according to Manfred Weslau, MD.

Samsung Bioepis Enters Breast and Gastric Market in Brazil

August 10th 2020

By Tony Hagen

Article

Samsung Bioepis makes a move into the promising Brazilian market for biosimilars, which data suggest is one of the fastest-growing biosimilars markets among emerging nations.

CinnaGen Biosimilar Shows Promise in Treating COVID-19

August 7th 2020

By Skylar Jeremias

Article

A new study showed that biosimilar interferon beta-1a (IFN-β-1a) may be effective in helping to treat patients with coronavirus disease 2019 (COVID-19).

Lyman Reassures on Biosimilar Quality

August 6th 2020

By Tony Hagen

Article

Originator biologics should be monitored as closely as biosimilars, according to Gary Lyman, MD, MPH, of the Hutchinson Institute for Cancer Outcomes Research.

Samsung Bioepis Appeals to Patients Through Package Design

August 6th 2020

By Tony Hagen

Article

In an award-winning attempt to get closer to patients, Samsung Bioepis has replaced harsh typography with white backgrounds and gentle shapes on its new biosimilar packaging.

Anti-TNF Biologics Outperform in Crohn Disease

August 6th 2020

By Deana Ferreri, PhD

Article

A real-world study on inflammatory bowel disease employing originator and biosimilar biologics suggests anti–tumor necrosis factor (TNF) therapy may be more effective for Crohn disease than for ulcerative colitis.

ASCO Study: Mandatory Drug Licensing Can Bridge Care Divide

August 5th 2020

By Skylar Jeremias

Article

Biosimilars have improved access to health care in India, but many effective new drugs are high priced and patented, and authors of a new study recommend interventions to make these available, too.